Altimmune's Phase 2b trial data reveal that pemvidutide, a dual glucagon/GLP-1 receptor agonist, significantly improves multiple non-invasive markers of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis after 24 weeks. AI-based digital pathology confirmed notable fibrosis regression, with up to 68.6% of patients showing improvement versus placebo. These results highlight pemvidutide's potential to treat MASH by addressing liver fat, inflammation, and fibrosis simultaneously. Based on these promising findings, Altimmune plans to start a Phase 3 trial later in 2026 to further evaluate pemvidutide's efficacy.
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
